Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.67 |
| ▸ | JAK2 | O60674 | 2/20 | 0.65 |
| ▸ | TYK2 | P29597 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.58 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ULK1 | O75385 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24006041 | 0.94 | POLB (0.69) | NT5EPTGS1JAK2TYK2KDM4E | |
| SCHEMBL24003984 | 0.89 | KCNK3 (0.61) | NT5EPTGS1JAK2TYK2POLB | |
| SCHEMBL2127722 | 0.88 | PTGS1 (0.77) | PTGS1KDM4EL3MBTL1NPC1RAB9A | |
| SCHEMBL24010211 | 0.86 | MAPT (0.58) | NT5EPTGS1JAK2TYK2KDM4E | |
| SCHEMBL31171945 | 0.85 | PTGS1 (0.72) | PTGS1KDM4EPOLBMAPTLMNA | |
| SCHEMBL309467 | 0.85 | PTGS1 (0.72) | PTGS1KDM4EPOLBMAPTLMNA | |
| SCHEMBL1352405 | 0.85 | PTGS1 (0.68) | PTGS1KDM4ENPC1RAB9APOLB | |
| SCHEMBL3646841 | 0.84 | NT5E (0.68) | NT5EJAK2TYK2KDM4EL3MBTL1 | |
| SCHEMBL14345056 | 0.84 | KCNK3 (0.71) | PTGS1JAK2TYK2KDM4EL3MBTL1 | |
| SCHEMBL24010595 | 0.83 | KMT2A (0.51) | NT5EPTGS1JAK2TYK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427566-B2 | Compounds useful for treating cancer | ABIVAX (FR) | 2022-08-30 | — | — | US | disclosed |
| US-20200239444-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2020-07-30 | — | — | US | disclosed |
| US-10717724-B2 | Compounds useful for treating cancer | ABIVAX (FR) | 2020-07-21 | — | — | US | disclosed |
| US-20180222888-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2018-08-09 | — | — | US | disclosed |
| US-9969715-B2 | Compounds useful for treating cancer | ABIVAX (FR) | 2018-05-15 | — | — | US | disclosed |
| CN-104903293-B | Novel anti-invasive compounds | ABIVAX公司 | 2016-08-24 | — | — | CN | disclosed |
| EP-2900635-B1 | NEW ANTI-INVASIVE COMPOUNDS | ABIVAX (FR) | 2016-07-13 | — | — | EP | disclosed |
| US-20150315173-A1 | NEW ANTI-INVASIVE COMPOUNDS | UNIVERSITE DE MONTPELLIER (FR) | 2015-11-05 | — | — | US | disclosed |
| CN-104903293-A | Novel anti-invasive compounds | ABIVAX | 2015-09-09 | — | — | CN | disclosed |
| EP-2900635-A1 | NEW ANTI-INVASIVE COMPOUNDS | ABIVAX (FR) | 2015-08-05 | — | — | EP | disclosed |
| US-5922711-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, AUTOIMMUNE DISEASES, SHOCK OR ANALGESICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-07-13 | — | — | US | disclosed |
| EP-0596406-B1 | Imidazo (1,2-a) Pyridines as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-12-16 | — | — | EP | disclosed |
| US-5750699-A | HALOGENATING OF CORRESPONDING COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| US-5708173-A | PREPARATION OF SUBSTITUTED QUINOLINE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-01-13 | — | — | US | disclosed |
| US-5574042-A | ANTAGONIST FOR BRADYKININS AS ANTIALLERGENS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, SHOCK OR PAIN | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 1996-11-12 | — | — | US | disclosed |
| US-5563162-A | CAN BE ADMINISTERD FOR THE TREATMENT OF ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASES, SHOCK OR PAIN IN ANIMALS AND HUMANS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-08 | — | — | US | disclosed |
| EP-0622361-A1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-02 | — | — | EP | disclosed |
| EP-0596406-A1 | Imidazo (1,2-a) Pyridines as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-05-11 | — | — | EP | disclosed |
| EP-0266897-A1 | Synthesis of alkylsulfinyl substituted 2-phenylimidazo [4,5-c] pyridines | ELI LILLY AND COMPANY (US) | 1988-05-11 | — | — | EP | disclosed |
| US-4740599-A | Synthesis of alkylsulfinyl substituted 2-phenylimidazo(4,5-c)pyridines | ELI LILLY AND COMPANY (US) | 1988-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222888-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | PRMT7, PRMT6, RRM2 | NT5E 1143/4885PTGS1 3464/4885JAK2 1551/4885 |
| US-20150315173-A1 | NEW ANTI-INVASIVE COMPOUNDS | MIF, MMP7, MMP8 | NT5E 427/4885PTGS1 1946/4885JAK2 1765/4885 |
| US-10717724-B2 | Compounds useful for treating cancer | PRMT7, PRMT6, RRM2 | NT5E 1143/4885PTGS1 3464/4885JAK2 1551/4885 |
| US-20200239444-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | PRMT7, PRMT6, RRM2 | NT5E 1913/4885PTGS1 3347/4885JAK2 1470/4885 |
| US-11427566-B2 | Compounds useful for treating cancer | PRMT7, PRMT6, RRM2 | NT5E 1913/4885PTGS1 3347/4885JAK2 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.